Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborator:
Exelixis
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01639508
First received: July 10, 2012
Last updated: May 19, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2016
  Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
No publications provided by Memorial Sloan Kettering Cancer Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):